Stock SILF HEMOGENYX PHARMACEUTICALS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Hemogenyx Pharmaceuticals Plc

Equities

SILF

GB00BYX3WZ24

Delayed London S.E.
Other stock markets
 11:27:50 29/04/2024 BST 		5-day change 1st Jan Change
1.623 GBX -1.64% Intraday chart for Hemogenyx Pharmaceuticals Plc +0.50% -29.43%
04-25 EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout AN
04-25 Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout
Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023
Hemogenyx Pharmaceuticals raises money for leukaemia treatment
Hemogenyx Pharmaceuticals Raises $4.2 Million via Share Placing
Hemogenyx Pharmaceuticals Achieves Breakthrough in Brain Cancer Treatment
Hemogenyx shares rise on potential for CBR to treat brain diseases
Hemogenyx Pharmaceuticals plc Announces CBR Brain Delivery
Hemogenyx Pharmaceuticals Tests Intranasal Delivery for Viral Infections Treatment
Hemogenyx says CBR can be used intranasally to treat viral infections
Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold
US FDA Removes Clinical Hold on Hemogenyx Pharmaceuticals' Acute Myeloid Leukemia Treatment
Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T
Hemogenyx Pharmaceuticals Obtains US Conditioning Patent
Hemogenyx hails US patent application progress
Hemogenyx Pharmaceuticals plc Announces Approval and Issuance of U.S. Conditioning Patent
Hemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDA
Hemogenyx Files Complete Response to US FDA's Clinical Hold of Leukemia Treatment Application
Hemogenyx Pharmaceuticals completes process qualification run
Hemogenyx Pharmaceuticals Wraps Up HEMO-CAR-T Process Qualification Run Following Clinical Hold
Hemogenyx Pharmaceuticals plc Announces Successful Completion of Its Process Qualification Run of the End-To-End Process for the Manufacture of HEMO-CAR-T Cells
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SILF Stock
  4. News Hemogenyx Pharmaceuticals Plc
  5. Other languages